Funding co-led by Northpond Ventures and S3 Ventures, positions QbDVision to build on the momentum generated through top-tier enterprise customer acquisitions and successful global deployments

AUSTIN, Texas: #DigitalCMC--QbDVision® Inc., the leading Digital CMC platform (Chemistry, Manufacturing, and Controls) for the life sciences industry, today announced the close of $13 million in new financing, bringing the total of its Series A funding to $28 million. This investment was fueled by enterprise customer growth, successful global deployments and increased demand for its category-defining Digital CMC platform. Today, their customers include three of the top six global pharma and biotech companies. The round was co-led by prior investors Northpond Ventures and S3 Ventures, along with Create Health Ventures, and other company insiders.

This financing will enable QbDVision to expand its commercial operations and accelerate its mission to establish Digital CMC as a strategic knowledge foundation for the future of drug development, helping organizations better manage complexity, drive operational excellence, and unlock AI-powered innovation.

“CMC is now center stage as a strategic priority for drug developers, and the need for digital transformation in this area has never been greater,” said Yash Sabharwal, President, CEO, and Co-Founder of QbDVision. “With global supply chains in flux, regulatory expectations evolving, and new therapeutic modalities becoming more complex, biopharma companies must modernize their CMC operations to remain competitive. QbDVision’s platform gives them the structured and contextualized knowledge they need to move faster, innovate smarter, and navigate uncertainty with confidence.”

Since its founding, QbDVision has enabled a fundamental shift required for Biopharma digital transformation. A movement away from siloed, document-centric legacy workflows and towards an integrated platform where CMC data is converted into a strategic knowledge asset. QbDVision is the force that can finally bring down the old barriers between teams, sites, organizations, and regulatory agencies. By structuring, curating, and linking this data captured throughout the product lifecycle, companies leverage a shared source of truth to accelerate development and manufacturing timelines, improve regulatory readiness, and lay the foundation for AI-driven innovation.

"QbDVision is addressing one of the most overlooked areas in biopharma digitalization. While discovery and clinical development have seen tremendous innovation, CMC has remained largely stagnant,” said Paxton Major, Managing Director at Northpond Ventures. “Their innovative platform and vision can fundamentally alter how our industry executes, helping companies lay the digital knowledge foundation for intelligent, AI-powered pharma operations. In today’s environment, with heightened pressures around manufacturing resilience and regulatory readiness, these capabilities are essential and facilitate the opportunities AI presents in accelerating the development of much-needed new medicines."

Digital CMC: Empowering a smarter, more agile future for biopharma

As the biopharmaceutical sector adapts to challenges ranging from supply chain disruption to globalization trends reversing in favor of onshoring, companies urgently need ways to manage and transfer critical CMC knowledge more effectively. Regulatory bodies also call for structured, transparent CMC data in future digital submission and review processes.

By delivering an intelligent, structured approach to managing CMC data and workflows digitally, QbDVision is helping companies improve operational efficiency and prepare for a future where AI-driven methods will dominate drug development and manufacturing.

“Just as AlphaFold required structured, curated scientific information to build powerful predictive models to unlock the power of AI in drug development, the predictive CMC models of the future will require the trustworthy and highly contextualized CMC knowledge that QbDVision delivers,” said Sabharwal.

For more information, please visit: www.qbdvision.com/structured-platform.

About QbDVision

QbDVision is a structured, cloud-based platform designed to empower teams with unified knowledge of their product and manufacturing process, while automating key development workflows throughout the entire product lifecycle journey. Unlike other traditional product lifecycle management (PLM) solutions, QbDVision’s Digital CMC platform is purpose-built for biopharma organizations to accelerate the development of life-changing therapies as they transition from R&D to Commercial Manufacturing. Teams can now leverage robust CMC knowledge that provides real-time guidance for enhanced data-driven decision making and streamlines complex operational workflows (e.g. tech transfer) that reduces cycle times, while ensuring quality and compliance. To learn more, please visit QbDVision.com or LinkedIn.

Fonte: Business Wire